Home/Filings/4/0001209191-24-003274
4//SEC Filing

Hill Stephen J. 4

Accession 0001209191-24-003274

CIK 0001806952other

Filed

Feb 12, 7:00 PM ET

Accepted

Feb 13, 8:24 PM ET

Size

11.1 KB

Accession

0001209191-24-003274

Insider Transaction Report

Form 4
Period: 2024-02-09
Hill Stephen J.
Chief Operating Officer
Transactions
  • Award

    Common Stock

    2024-02-09+40,00048,928 total
  • Award

    Stock Option (right to buy)

    2024-02-09+400,000400,000 total
    Exercise: $1.80Exp: 2034-02-08Common Stock (400,000 underlying)
Footnotes (3)
  • [F1]The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  • [F2]Includes 2,941 shares acquired on May 18, 2022, 5,434 shares acquired on May 18, 2023 and 553 shares acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan.
  • [F3]12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.

Issuer

Lyell Immunopharma, Inc.

CIK 0001806952

Entity typeother

Related Parties

1
  • filerCIK 0001866154

Filing Metadata

Form type
4
Filed
Feb 12, 7:00 PM ET
Accepted
Feb 13, 8:24 PM ET
Size
11.1 KB